Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $15.85M fell 22.4% year over year, behind the -1.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.6% from the prior quarter. Over 3 fiscal years it compounded at -65.2% a year.
Context
- Stock-based compensation amounted to 47.9% of revenue in FY2025, down 1.6 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -22.4% toward the trailing-twelve-month pace of -1.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 81.55M USD
- Year-over-year change
- -27.4%
- 4-year CAGR
- -52.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.55M | -27.4% |
| FY2024 | 2024-12-31 | 112.34M | -51.1% |
| FY2023 | 2023-12-31 | 229.88M | -88.1% |
| FY2022 | 2022-12-31 | 1.93B | +20.2% |
| FY2021 | 2021-12-31 | 1.61B | — |
Stock-Based Compensation vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.5% is the 5th highest of 9, against a peer median of +5.3%.
- Stock-based compensation amounts to 54.5% of revenue for DNA, versus a peer median of 16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $76.97M USD | -1.5% | -65.2% | 54.5% | |
| LTM Mar 2026 | $47.93M USD | +107.3% | -8.3% | 60.1% | |
| LTM Sep 2026 | $46.65M USD | -42.2% | -9.8% | 12.3% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $41.75M USD | +456.0% | +204.9% | — |
| LTM Mar 2026 | $35.01M USD | +17.1% | -21.7% | 53.5% | |
| LTM Dec 2025 | $32.43M USD | -6.5% | +13.1% | — | |
| LTM Jun 2026 | $26M USD | -36.2% | — | 12.5% | |
| LTM Mar 2026 | $18.8M USD | -77.8% | -16.5% | 21.0% | |
| LTM Mar 2026 | $15.73M USD | +224.1% | +209.1% | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding DNA) | — | +5.3% | -8.3% | 16.7% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.84B) | (2.11B) | (892.87M) | (547.03M) | (312.76M) |
| Depreciation & Amortization | 29.08M | 42.55M | 71.55M | 63.02M | 58.99M |
| Deferred Income Tax | 30.21M | (14.61M) | (801K) | (936K) | (1.36M) |
| Stock-Based Compensation | 1.61B | 1.93B | 229.88M | 112.34M | 81.55M |
| Change in Working Capital | (61.54M) | (37.01M) | 29.84M | (89.67M) | (44.09M) |
| Accounts Receivables | (114.09M) | 55.02M | 50.07M | (4.73M) | (1.47M) |
| Inventory | (626K) | 164K | 0 | 0 | 0 |
| Accounts Payables | (2.25M) | (10.84M) | (1.18M) | 4.77M | (2.99M) |
| Other Working Capital | 55.43M | (81.35M) | (19.05M) | (89.72M) | (39.62M) |
| Other Non-Cash Items | (20.95M) | (67.4M) | 266.9M | 142.69M | 46.62M |
| Operating Cash Flow | (253.82M) | (252.2M) | (295.5M) | (319.59M) | (171.06M) |
| Capital Expenditures | (56.52M) | (52.27M) | (40.8M) | (62.54M) | (7.67M) |
| Acquisitions (Net) | (12.04M) | 26.65M | (38.55M) | (5.4M) | 0 |
| Purchases of Investments | (5M) | (3.69M) | 0 | 0 | (418.63M) |
| Sales of Investments | 0 | 0 | 0 | 4.52M | 185.38M |
| Other Investing Activities | 304K | (38.08M) | (1.34M) | 1.19M | 624K |
| Investing Cash Flow | (73.26M) | (67.39M) | (80.69M) | (62.24M) | (240.29M) |
| Debt Repayment | (1.12M) | (1.24M) | (1.3M) | (897K) | (354K) |
| Common Stock Issued | 0 | 99.3M | 0 | 80K | 19.47M |
| Common Stock Repurchased | (25M) | 0 | (23K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.56B | (2.73M) | (1.43M) | (922K) | (1.34M) |
| Financing Cash Flow | 1.53B | 95.34M | (3.22M) | (1.74M) | 17.78M |
| Effect of Forex Changes | (19K) | 908K | (588K) | (281K) | 395K |
| Net Change in Cash | 1.21B | (223.35M) | (380M) | (383.84M) | (393.18M) |
| Free Cash Flow | (310.34M) | (304.47M) | (336.3M) | (382.13M) | (178.72M) |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.